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Quality in Non-Licensed 
Radiopharmaceutical Products: 
Are We Achieving the Goal?
Estrella Moya Sánchez
Abstract
Radiopharmaceutical compounds, considered a special group of medicines, can 
be prepared outside the marketing authorisation track. Small-scale preparations 
at non-commercial sites thereby represent an important segment, however a lack 
of harmonisation in the regulation leads to extreme differences in the application 
and availability of radiopharmaceuticals across Europe. A number of guidelines 
and guidance documents have been issued by European Association of Nuclear 
Medicine (EAMN), Pharmaceutical inspection convention (PICs), European 
Directorate for the Quality of Medicines & HealthCare (EDQM) to achieve a good 
radiopharmacy practice for small-scale preparation. Nevertheless, in the case of 
non-licensed radiopharmaceuticals their consideration as magistral formulas, in 
some countries, makes it possible to waive regulatory inspections aimed to ensure 
those good practices enforcement. Moreover, special attention should be put on 
the quality assurance process for non-licensed starting materials, given that the 
final radiopharmaceuticals quality chiefly depends on it. This paper (chapter) will 
provide an insight into the quality standards applicable to starting materials, such as 
supplier qualification control, starting material re-test period, etc. in order to raise 
for discussion about how best to achieve a proven quality, efficacy, and safety for 
our radiopharmaceuticals (licensed or non-licensed).
Keywords: non-licensed, good radiopharmacy practice, magistral formulas,  
quality assurance process
1. Introduction
During the ‘80s radiopharmaceuticals were considered as tracers used in hospital 
centres under the responsibility of a person with a sound knowledge in the safe use 
of radiation. It was in 1989 when radiopharmaceuticals were considered for the first 
time in the European Union as medicinal products after entry into force the Council 
Directive 89/343/EEC [1]. In this Directive was stated the first official radiopharma-
ceutical definition as:
“any medicinal product which, when ready for use, contains one or more radionu-
clides (radioactive isotopes) included for a medicinal purpose.”
Radiopharmaceuticals are used in major clinical areas for diagnosis and therapy. 
They usually have no pharmacologic effects, as they are used in tracer quanti-
ties. Consequently, there is no dose–response relationship, which thus differs 
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significantly from conventional medicinal products. Radiation is an inherent 
characteristic of all radiopharmaceuticals, and patients always receive an unavoid-
able radiation dose. In the case of therapeutic radiopharmaceuticals, radiation is 
what produces the therapeutic effect.
The manufacturing and handling of radiopharmaceuticals is potentially haz-
ardous. The level of risk depends in particular upon the types of radiation, the 
energy of radiation and the half-lives of the radioactive isotopes. The facilities and 
procedures for the production, use, and storage are subject to licencing by national 
and/or regional authorities. This licencing includes compliance both with regula-
tions governing pharmaceutical preparations and with those governing radioactive 
materials.
Considering the special nature of radiopharmaceuticals, strict adherence to 
conventional good manufacturing practices is not possible in many scenarios 
where radiopharmaceuticals are handled. It is necessary to balance aseptic handling 
practices (patient safety) with radiation protection practices (worker safety) 
complying with the current As Low As Reasonably Achievable (ALARA) require-
ments. Moreover, a demanding technical difference and challenge is that in most 
cases, diagnostic radiopharmaceuticals need to be prepared, controlled and used 
within a short time of a few hours or even minutes due to the physical half life of the 
radionuclides.
Specific guidance is available on adaptations to the conventional regulatory 
framework to address challenges of the preparation of radiopharmaceuticals.
2. Medical uses of radiopharmaceuticals
A radionuclide may decay by emitting different types of ionising radiation: alpha 
(α), beta (β-), positron (β+) and gamma (γ) radiation.
Depending on the radiation characteristics of the radionuclide, the radiophar-
maceutical is used either for diagnosis or for therapy. Diagnostic radiopharmaceu-
ticals should decay by gamma emission like Technetium-99 m (99mTc), Iodine-123 
(123I) and Galium-67 (67Ga) or positron emission like Fluorine-18 (18F), 
Oxygen-15 (15O), Carbon-11 (11C), Zirconium 89 (89Zr) and Gallium 68 (68Ga) 
and never emit alpha particles or even beta particles.
On the other hand, therapeutic radiopharmaceuticals should decay by 
particulate decay (alpha or beta) since the intended effect is in fact radiation 
damage to specific cell, examples of β -emitters are Rhenium-186/Rhenium-188 
(186Re/188Re), Strontium-89 (89Sr), Lutetium-177 (177-Lu),Iodine-131 (131-I) 
and Yttrium-90 (90Y) and of therapeutic α-emitters are Actinium-225 (225Ac), 
Bismuth-213 (213Bi) and Astatine-211 (211At).
Moreover, there is an emerging field of nuclear medicine named theranostics 
(Therapeutics and diagnostics), that involves diagnostic and therapeutic agents to 
target diseased cells and tissues. The use of targeting molecules labelled either with 
diagnostic radioisotopes and with therapeutic isotopes enables a more complete 
approach to patient management, because the diagnosis can then serve several 
simultaneous functions: assessing disease, monitoring and selection for therapy. 
The prospects of identifying the disease and orienting treatment, provide an 
advance level in precision medicine.
One of the most common examples of theragnosis in nuclear medicine is the 
use of Gallium 68(68Ga) as a diagnostic radiopharmaceutical, followed by therapy 
with radionuclides such as Lutetium 177 (177-Lu) to label the same molecule in the 
context of personalised therapy.
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3.  Radiopharmaceutical’s dosage forms. Alternative methods to control 
sterility in radiopharmaceuticals
Radiopharmaceuticals are medicinal products on prescription that can be 
delivered orally (in pill form), intravenously (injected into a patient’s vein) 
or interstitially (inserted into a cavity in the body). The intravenous route of 
administration is the most used in Radiopharmaceuticals application. According 
to the European Pharmacopoeia monograph regarding Radiopharmaceutical 
preparations (01625) [2], these products must be sterile as stated in the following 
extract.
“Radiopharmaceutical preparations for parenteral administration comply with the 
test for sterility. They must be prepared using precautions designed to exclude microbial 
contamination and to ensure sterility. The test for sterility is carried out as described in 
the general method (2.6.1).” [3].
Moreover, the pharmacopoeia also considers the specific nature of radiopharma-
ceuticals, as specified in this other extract.
“Special difficulties arise with radiopharmaceutical preparations because of the short 
half-life of some radionuclides, the small size of batches and the radiation hazards. In the 
case that the monograph states that the preparation can be released for use before comple-
tion of the test for sterility, the sterility test must be started as soon as practically possible 
in relation to the radiation.”
With the conventional sterility method (2.6.1) [3] the portions of the media 
should be incubated for 14 days. Though the test must be started as soon as practi-
cally possible in relation to the radiation, it will take several days to achieve a safe 
level of exposure. This means that sterility testing results would be available around 
three weeks after the radiopharmaceutical preparation. Consequently, the outcomes 
of the tests when following this method seldom enable proactive corrective actions 
to be taken in case a lack of sterility is detected.
Alternative methods for control of microbiological quality have been described 
in European Pharmacopoeia (5.1.6) [4]. They have shown potential for real-time 
o near real-time results with the possibility of earlier corrective action. Although 
this pharmacopoeia chapter is published for information, these new methods, if 
validated and adapted for routine use can also offer significant improvements in the 
quality of testing.
Similarly, USP has another monograph (1071) [5] where the following extract 
can be found.
“Rapid microbial tests for release of sterile short-life products: a risk-based 
approach”.
In this chapter, positron emission tomographic (PET) products are mentioned as 
an example where these rapid methods could be applied.
“It is widely recognized that the current growth-based sterility tests with an incuba-
tion period of at least 14 days are not suitable for products with a short shelf-life or for 
products prepared for immediate use, which are usually infused into patients before the 
completion of the test (1). These short-life products include compounded sterile prepara-
tions (CSPs), positron emission tomographic (PET) products, and cell and gene 
therapies, which require a new generation of risk-based approaches that include rapid 
microbial tests”.
The information provided in these pharmacopoeia chapters may be used as a 
supplement or as an alternative microbiological method and to give guidance on 
validation of the chosen method. It is neither the intention to recommend one 




In both chapters, European Pharmacopoeia (5.1.6) [4] and USP monograph 
(1071) [5], it is stated that risk analysis tools may be used to determine which 
alternative method is to be implemented as well as to balance user requirement 
specification including time to result, specificity, limit of detection (LOD), sample 
size, and product attributes. The microbiological alternative methods proposed in 
European Pharmacopoeia and USP are described in Table 1.
4. Types of radiopharmaceutical marketing authorisations
Licensed radiopharmaceuticals manufactured under GMP requirements.
In the European Union, radiopharmaceutical compounds are considered a 
special group of medicines. Their manufacturing/preparing and uses are regulated 
by directives and regulations that must be adopted by Member States. (Directive 
2001/83/EC [6] and Regulation (EC) No 726/2004 [7]).
For a radiopharmaceutical to be available on the market, sold and marketed, it 
needs to have a marketing authorisation. The marketing authorisation application 
must provide evidence of the efficacy, safety, and quality of the radiopharmaceuti-
cal. When applying for a marketing authorisation for a radiopharmaceutical, the 
marketing authorisation application is submitted to a regulatory authority, which 
will assess the medicinal product’s pharmaceutical and chemical quality, efficacy, 
and safety, as well as its risk–benefit ratio.
Rapid microbial tests described in USP (1071)
• Adenosine triphosphate bioluminescence
• Flow cytometry
• Isothermal microcalorimetry
• Nucleic acid amplification
• Respiration
• Solid phase cytometry
Alternative methods for control of microbiological quality described in Ph. Eur 5.16
There are 3 major types of determination specific to microbiological tests:
1. Qualitative tests for the presence or absence of micro-organisms:
• Tests based on bioluminescence
• Solid phase cytometry
• Gas detection or autofluorescence
•  Nucleic acid amplification techniques (NAT) (2.6.21) may also be used for the detection of 
 mycoplasmas (2.6.7)
2. Quantitative tests for enumeration of micro-organisms:
• Autofluorescence
• Flow cytometry
• Direct epifluorescent filter technique (DEFT)
• Solid phase cytometry
3. Identification tests
• Biochemical and morphological characterisation
Table 1. 
List with alternative methods of microbiological quality described in pharmacopoeia European and USP.
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In the EU, there are four types of marketing authorisation application 
procedures. These procedures can be found in European Medicines Agency 
(EMA) website [8] in its section devoted to medicine for human use marketing 
authorisations:
• National procedure: Used when applying for a marketing authorisation in one 
individual EU Member State, Norway, Iceland, and Liechtenstein.
• Centralised procedure: The centralised procedure allows manufacturers to 
submit a single Market Authorization Application (MAA) to the European 
Medicines Agency (EMA) who is responsible for the scientific evaluation. Once 
granted by the European Commission, the centralised marketing authorisa-
tion is valid in all European Union (EU) Member States, Iceland, Norway and 
Liechtenstein.
The centralised procedure is compulsory for:
• Human medicines containing a new active substance to treat:




 ○ neurodegenerative diseases;
 ○ auto immune and other immune dysfunctions;
 ○ viral diseases.
• Medicines derived from biotechnology processes, such as genetic engineering.
• Advanced-therapy medicines, such as gene-therapy, somatic cell-therapy or tissue-
engineered medicines.
• Orphan medicines (medicines for rare diseases).
• Veterinary medicines for use as growth or yield enhancers.
It is optional for other medicines:
• Containing new active substances for indications other than those stated above.
• That are a significant therapeutic, scientific, or technical innovation.
• Whose authorisation would be in the interest of public or animal health at 
EU level.
Today, the great majority of new, innovative medicines pass through the  
centralised authorisation procedure in order to be marketed in the EU.
Radiopharmaceuticals
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If a company wishes to request marketing authorisation in several EU Member 
States for a medicine that is outside the scope of the centralised procedure, it may 
use one of the following routes, as also clarified in the EMA website:
• Decentralised Procedure: The procedure for authorising medicines whereby 
a medicine that has not yet been authorised in the EU can be simultaneously 
authorised in several EU Member States.
• Mutual Recognition Procedure: The procedure for authorising medicines 
whereby a marketing authorisation granted in one Member State can be recog-
nised in other EU countries.
In case of Radiopharmaceuticals, that are used extensively to treat people with 
cancer, centralised procedure will be the proceeding to be followed.
4.1 Radiopharmaceuticals within a clinical trial
On the other hand, the Radiopharmaceuticals can be used for research and 
development. All requirements to apply in Europe for a clinical trial are stated in 
EudraLex - Volume 10 - Clinical trials guidelines Volume 10 of the publication “The 
rules governing medicinal products in the European Union” [9].
The following four circumstances are possible for the use of 
Radiopharmaceutical within a clinical trial:
• Licensed radiopharmaceutical products used within their authorised 
indications,
• Licensed radiopharmaceutical products used outside their authorised 
indications,
• Radiopharmaceuticals having established clinical use that are prepared in 
accordance with approved regulations and meet approved quality require-
ments (e.g. as described in a monograph of a pharmacopoeia),
• New radiopharmaceuticals or tracer agents outside the previous categories.
4.2 Small scale preparations of radiopharmaceuticals
Radiopharmaceuticals may be prepared at small scale in healthcare establish-
ments, and they may also be prepared outside the marketing authorisation track.
There are various types of radiopharmaceuticals prepared in healthcare 
establishments as it is described in PIC/S (Pharmaceutical inspection convention, 
pharmaceutical inspection co-operation scheme) [10] among which can remark:
• Sterile products with a marketing authorisation which are aseptically prepared 
in the healthcare establishment. These are typically used for routine diagnostic 
purposes in nuclear medicine and include:
• Technetium- 99 m radiolabelled ligands obtained by the combination of the kit 
component with [99mTc] pertechnetate from a radionuclide generator.
• Radionuclide precursors with a marketing authorisation, for example 
Yttrium-90 which are used as starting materials for synthesis.
7
Quality in Non-Licensed Radiopharmaceutical Products: Are We Achieving the Goal?
DOI: http://dx.doi.org/10.5772/intechopen.99388
• Sterile products without a marketing authorisation which are synthesised, 
radiolabelled, purified and formulated for diagnostic or therapeutic use.
• Oral products with marketing authorisation which are prepared as capsules  
or solutions which the patient takes for diagnosis or therapeutic. Use  
(e. g. Iodine-131 for thyroid treatment).
5. Preparation or manufacturing of radiopharmaceuticals?
The difference between radiopharmaceutical preparation and manufacture is a 
sensitive issue which calls for a consensus that, it seems not exist at present.
The following definitions for preparation and manufacturing can be found in 
the GMP Annex 3 [11]:
“Preparation: handling and radiolabelling of kits with radionuclide eluted from 
generators or radioactive precursors within a hospital. Kits, generators and precursors 
should have a marketing authorisation or a national licence”.
“Manufacturing: production, quality control and release and delivery of radiophar-
maceuticals from the active substance and starting materials”.
As per the extract above, it becomes apparent that in a preparation, products 
with marketing authorisation should be used. Provided that the summary of prod-
uct characteristics (SPC) instructions is followed, the ultimate responsibility for 
the radiopharmaceutical preparation with respect to its safety, quality, and efficacy, 
over its shelf live lies with the marketing authorisation holder (MAH). However, 
this requirement is not remarked in the case of manufacturing.
By contrast, if we regard the Pharmacopoeia European monograph (5.19) 
Extemporaneous preparation of radiopharmaceuticals [12], the following definition 
is stated:
“The preparation of radiopharmaceuticals is considered as a process involving some 
or all of the following steps: purchase of materials and products, production of radio-
nuclides for radiolabelling, radiolabelling, chemical modification and/or purification, 
formulation, dispensing of the pharmaceutical form, sterilisation, analytical control, 
packaging, labelling and release. Drawing patient doses for immediate application  
(e.g., from a multidose vial) is considered as part of clinical practice, and not part of the 
preparation of Radiopharmaceuticals.”
As can be seen in the pharmacopoeia definition, the use of authorised materials 
and products is not a requirement. From this perspective, preparation and manu-
facturing processes could seem fairly similar, since purification and sterilisation 
steps are also encompassed within them. However, as it is stated in Pharmacopoeia 
European monograph (5.19), the manufacture of radiopharmaceuticals and inves-
tigational medicinal products should be covered by existing regulation (authorisa-
tion of any competent authority) and a pharmaceutical preparation definition 
would include all the preparations with licensed and non-licensed products. 
Additionally, the European Pharmacopoeia monograph 2619 [13] differences two 
categories, extemporaneous and stock preparations as it can be seen in the  
following extracts:
“Pharmaceutical preparations are medicinal products generally consisting of active 
substances that may be combined with excipients, formulated into a dosage form suitable 
for the intended use, where necessary after reconstitution, presented in a suitable and 
appropriately labelled container.”
“Pharmaceutical preparations may be non-licensed by the competent authority, or 
unlicensed and made to the specific needs of patients according to legislation. There are 2 
categories of unlicensed pharmaceutical preparations:
Radiopharmaceuticals
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• extemporaneous preparations, i.e., pharmaceutical preparations individually 
prepared for a specific patient or patient group, supplied after preparation.
• stock preparations, i.e., pharmaceutical preparations prepared in advance and 
stored until a request for a supply is received.”
On the other hand, we cannot overlook that most radiopharmaceutical prepara-
tions are used for parenteral administration, and therefore required to be sterile. 
Then, if we consider the EMA guideline on the sterilisation of the medicinal product 
active substance, excipient, and primary container, [14] it might seem that whenever 
a sterilisation procedure has to be applied, it will be considered as a manufacturing 
process according to the following extract:
“Sterility is a critical quality that cannot be assured by testing, it needs to be assured 
by the use of a suitably designed, validated and controlled manufacturing process”.
Therefore, this consideration seems to contradict the previous pharmacopoeia 
extracts where the sterilisation process was included in the scope of the preparation 
definition.
Notwithstanding the difficulties to get an official consensus on the definitions 
of preparation and manufacturing, there should be an agreement on who bears the 
final responsibility in them:
• In the event licensed products were used, the responsibility would lie with the 
marketing authorisation holder (MAH) as long as the summary of product 
characteristics (SPC) instructions is followed. If these instructions include the 
need to apply sterilisation, the responsibility on the sterilisation process would 
also lie on the MAH.
• Otherwise, whenever non-licensed products or licensed products not 
compliant with SPC instructions were used, the final responsibility would 
always rest with the Chief Radiopharmacist who prepares/manufac-
tures them.
6. Scientific guidelines
As is stated in the EMA website [8] “The European Medicines Agency’s Committee 
for Medicinal Products for Human Use prepares scientific guidelines in consultation with 
regulatory authorities in the European Union (EU) Member States, to help applicants 
prepare marketing authorisation applications for human medicines. Guidelines reflect a 
harmonised approach of the EU Member States and the Agency on how to interpret and 
apply the requirements for the demonstration of quality, safety and efficacy set out in the 
Community directives”.
These guidelines are complementary to European Pharmacopoeia monographs 
and chapters, since as detailed in the directive 2001/83 EC (annex I) [6] with 
respect to the quality part (chemical, pharmaceutical and biological) of the dos-
sier, all monographs including general monographs and general chapters of the 
European Pharmacopoeia are applicable.
The catalogue of guidelines is categorised according to the Common Technical 
Document (CTD) [15] when they concern general issues and include the guidelines 
that are globally harmonised through the International Council on Harmonisation 
of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH).
9
Quality in Non-Licensed Radiopharmaceutical Products: Are We Achieving the Goal?
DOI: http://dx.doi.org/10.5772/intechopen.99388
The Guideline on Radiopharmaceuticals [16] issued by EMA Committee for 
human medicinal products provides information about specific requirements 
for radiopharmaceuticals in applications for both marketing and clinical trial 
authorisations.
Altogether, regulatory authorities and industry prepared ICH scientific guide-
lines as shown in Table 2.
However, CHMP scientific guidelines are just issued by the European Medicines 
Agency’s Committee for Medicinal Products for Human Use.
In addition to the application of the mentioned guidelines, the manufacturing 
process shall comply with the requirements of Commission Directive 91/356/EEC, 
as amended by Directive 2003/94/EC, and 91/412/EEC respectively laying down 
the principles and guidelines of Good Manufacturing Practice (GMP) for medicinal 
products for human use and with the principles and guidelines on GMP, published 
by the commission in the rules governing medicinal products in the European 
Community, Volume 4 [17]. In particular, the EU GMP annex 3 [11] specifically 
addresses some of the practices, which may be specific for radiopharmaceuticals.
Furthermore, there are also other guidelines published whose main objective is 
to harmonise inspection procedures worldwide by developing common standards 
in the field of GMPs and by providing training opportunities to Inspectors. They 
are issued by The Pharmaceutical Inspection Co-operation Scheme (PIC/S) who is 
a non-binding, informal co-operative arrangement between Regulatory Authorities 
in the field of Good Manufacturing Practice (GMP) of medicinal products for 
human or veterinary use. Particularly, the annex 3 of PIC/S Guide to good practices 
for the preparation of medicinal products in healthcare establishments is devoted to 
Radiopharmaceuticals [10].
Similarly, EDQM has published in the European Pharmacopoeia, the mono-
graph 5.19 Extemporaneous preparation of Radiopharmaceuticals [12]. Although 
this monograph is only for information, it covers guidance for preparing “kit-based 
preparations (from licensed and unlicensed kits) and unlicensed preparations 
containing radionuclides for positron emission tomography (PET), single photon 
emission computed tomography (SPECT) or for therapeutic applications”.
In the USP several monographs can also be found regarding radiopharma-
ceuticals preparation, such as USP (825) [18] radiopharmaceuticals preparation, 
compounding, dispensing and repackaging or USP (823) [19] Positron emission 
tomography drugs for compounding, investigational, and research uses.
Besides, other “for information” guidelines can be mentioned. For instance, a 
guideline to achieve a good radiopharmacy practice for small-scale preparation was 
issued by The European Association of Nuclear Medicine (EANM) [20]. This is a 
professional non-profit medical association that facilitates communication worldwide 
among individuals pursuing clinical and research excellence in nuclear medicine.
In conclusion, many guidelines and guidance documents have been issued to 
foster good radiopharmacy practices for licensed or not licensed radiopharmaceuti-
cals in both large and small-scale preparation.





Summary of the parties involved in the ICH guidelines development.
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7.  Radiopharmaceuticals preparation outside the marketing track in the 
European Union
In the European Union (UE), the community code relating to medicinal prod-
ucts for human use is regulated by the Directive 2001/83/EC [6] as amended. This 
Directive has to be adopted by Member States. The rate and extent of adoption and 
interpretation of the Directive varies among countries. Each Member State may intro-
duce changes, provided the general scope and limits of the directive is maintained.
In this way, several European Member States have set up a regulatory framework 
in which radiopharmaceuticals for routine use can be prepared on site without 
the requirements of a marketing authorization. These exemptions flow from the 
definitions in Article 3 of Directive 2001/83/EC [6], the so-called magistral and 
officinal formulae, and from Article 5(1) of Directive 2001/83/EC aimed to fulfil 
special needs.
The European Court of Justice. Document 62013CJ0544 and Judgement of the 
Court (Third Chamber) of 16 July 2015 has clarified both situations of Articles 3 
and 5 [21].
Considering article 3, for “magistral formulae” defined as “any medicinal 
product prepared in a pharmacy in accordance with a medical prescription for an 
individual patient”. The European Court of Justice specified that “[such a prepara-
tion] must of necessity be prepared on the basis of a prior prescription issued by a 
professional person qualified to do so”. This prescription must, in addition “be ‘for 
an individual patient’” and “that patient must be identified before the medicinal 
product is produced and it must be produced specifically for that patient”. It was 
also stated that “the exception provided for in that provision can only concern situa-
tions in which the doctor considers that the state of health of his individual patients 
requires that a medicinal product be administered for which there is no authorised 
equivalent on the national market, or which is unavailable on that market”, clearly 
excluding competition with licensed medicinal products.
Similarly, by virtue of Article 5(1) of Directive 2001/83 [6], to fulfil special 
needs, exclude from the provisions of that directive medicinal products supplied in 
response to a bona fide unsolicited order, formulated in accordance with the specifi-
cations of an authorised healthcare professional and for use by an individual patient 
under his direct personal responsibility. In that regard, the court has held that it is 
apparent from the conditions as a whole set out in that provision, read in the light 
of the fundamental objectives of that directive, and in particular the objective of 
seeking to safeguard public health, that the exception provided for in that provision 
can only concern situations in which the doctor considers that the state of health of 
his individual patients requires that a medicinal product be administered for which 
there is no authorised equivalent on the national market or which is unavailable 
on that market (see, to that effect, judgement in Commission v Poland, C-185/10, 
EU:C:2012:181, paragraphs 29 and 36).
United Kingdom (UK) is the clear example of applying the exception of art 
5(1) of the Directive 2001/83/EC [6], despite after Brexit is no longer part of the 
European Union (UE). The regulation 167 of the Human Medicines Regulations 
2012 sets out the exemption from the requirement for a medicinal product, 
placed on the market in the UK to hold a marketing authorisation. Additionally, 
the Medicines and Healthcare Products Regulatory Agency (MHRA) issued the 
MHRA Guidance Note 14 called “The supply of unlicensed medicinal products 
(“specials”). [22]
In some Member States (Austria, Belgium etc..) the preparation of PET radio-
pharmaceuticals could be considered, in many situations, as magistral formulas 
since they are prepared in accordance with a medical prescription for an individual 
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patient. The preparation of radiopharmaceuticals as magistral formulae is not 
covered under the Directive 2001/83/EC [6], therefore its legislation falls under the 
responsibility of each Member State.
In Germany, PET radiopharmaceuticals can be manufactured accord-
ing to the requirements set in article 13(2b) of the Medicinal Products Act 
(Arzneimittelgesetz, AMG) where it is stated that “a person who is a doctor or 
dentist or who is otherwise authorised to practise medicine on humans does not require 
a licence according to paragraph 1, insofar as the medicinal products are manufactured 
under his direct professional responsibility for the purpose of personal use on a specific 
patient”. However, it is important to note that the compliance with the Medicinal 
Products Act is controlled by the Federal States, coming along with the acceptance 
of varying practices by different state authorities. Hence, there is currently a lively 
discussion in the nuclear medicine community about minimum standards for this 
production, though the use of radiopharmaceuticals with marketing authorisation 
is preferential.
By contrast, in Spain, the preparation of radiopharmaceuticals cannot be con-
sidered as magistral formulae since they must be prepared with legally recognised 
action and indication substances as stated in Royal Legislative Decree RDL 1/2015. 
Therefore, the only way to prepare PET radiopharmaceuticals outside the marketing 
authorisation track would be under the regulatory framework of article 47.1c in Real 
Decree (RD) 1345/2007 on the marketing authorization procedure in medicines for 
human use [23]. This Decree completes the RDL 1/2015 [24], which is the trans-
position of Directive 2001/83/EC [6]. The article 47.1.c in the RD 1345/2007 [23] 
establishes the following criteria:
The marketing authorisation for PET radiopharmaceuticals will not be required, 
whenever they are prepared in an approved radiopharmaceutical unit under the 
supervision and control of a radiopharmaceutical specialist, provided that they 
meet the following requirements:
1. They are entirely prepared and used in the authorised radiopharmacy units 
with non-profit use and in centres linked to the National Health System.
2. They are substances used in clinical research, or medicines that the Spanish 
Agency for Medicines and Medical Devices (AEMPS) considers satisfying the 
guarantees of quality, safety, efficacy, identification, and information, and that 
are prepared in appropriate facilities.
Beyond the lack of alignment regarding the definition of radiopharmaceuticals 
preparations analysed above, differences can also be found with respect to the 
requirements that manufacturers have to comply with in their preparation. The 
following examples depict this situation:
• In United Kingdom as is stated in MHRA Guidance Note 14, [22] “the manu-
facturer or assembler of “specials” must hold a Manufacturer’s “Specials” 
Licence granted by the Licencing Authority.” Furthermore, it is also said that 
“the manufacturing/assembly site and its operations will be inspected for 
compliance with Good Manufacturing Practice (GMP) and the conditions of 
the licence”.
• In Spain the situation seems to be fairly like UK, the manufacturer must apply 
the Spanish Medicines Agency (AEMPS) for a certificate of compliance with 
requirements and the sites operations will be inspected for compliance with 
Good Manufacturing Practices (GMPs).
Radiopharmaceuticals
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• In the rest of the Member States there are different degrees of compliance with 
Good Manufacturing Practices (GMPs). In some countries as Germany full 
adherence to GMPs is required, while in other countries such as Italy special 
or adapted GMPs are enforced. Finally, there are other countries where this 
compliance is not clearly specified.
Summarising, there are different ways to carry out the radiopharmaceuticals 
small scale preparation outside the marketing authorisation track, depending on the 
national legislation in each Member State. Hence, a cornerstone of the radiophar-
maceutical’s preparation might currently be the lack of harmonisation at European 
level, especially regarding the quality standards applicable to these preparations.
Nevertheless, leaving aside the lack of harmonisation among countries, special 
attention shall be drawn to the achievement of the highest standard quality radio-
pharmaceutical preparations. It is a fact that, as a rule, this goal is accomplished in 
the manufacturing processes for medicinal products by applying GMPs. For sure, 
these practices should consider the special nature of radiopharmaceuticals balanc-
ing aseptic handling with radiation protection. Besides, authorities should ensure 
that manufacturers in their territory are subject to routine GMP inspections.
In the field of clinical trial this goal is on its way thanks to the new Regulation 
536/2014 [25] repealing the Directive 2001/20/EC. This regulation will achieve the 
harmonisation between Member States, through the creation of a uniform regulatory 
framework for the authorization of clinical trials. It is to be noted that European 
Regulations are not transposed by the European Members but directly applied. 
Therefore, European Member States shall be compliant with this regulation.
The Regulation 536/2014 [25], in the case of radiopharmaceuticals used in 
clinical trials stablishes differences between therapeutic and diagnostic radiophar-
maceuticals. While therapeutic radiopharmaceuticals are considered as any other 
medicinal product used in a Clinical Trial, regarding diagnostic radiopharmaceu-
ticals substantial changes are introduced by the following article (Art. 61.5.b of 
Regulation 536/2014):
“preparation of radiopharmaceuticals used as diagnostic investigational medicinal 
products where this process is carried out in hospitals, health centers or clinics, by 
pharmacists or other persons legally authorized in the Member State concerned to carry 
out such process, and if the investigational medicinal products are intended to be used 
exclusively in hospitals, health centers or clinics taking part in the same clinical trial in 
the same Member State”.
Based on the analysis of this article in conjunction with other relevant ones of 
this regulation it is observed that:
1. The authorization for manufacturing and import for the radiopharmaceuticals 
included in the art. 61.5.b is not needed.
2. GMPs to produce the Radiopharmaceuticals included in the exception of 
art. 61.5.b seems not to be needed. Because of Regulation 536/2014, two new 
legislation documents in relation to GMP have been released: (1) Directive 
2017/1572 [26], the new GMP Directive that repeals the old GMP Directive 
2003/94; and (2) Regulation 2017/1569 [27], a new GMP Regulation for IMPs 
(Investigational Medicinal Products) that does not apply to those radiophar-
maceuticals included in art. 61.5.b of Regulation 536/2014. However, apparent-
ly contradicting the previous exception, this regulation remarks that Member 
States could carry on regular inspections to ensure subject safety and reliability 
and robustness of the data generated in the clinical trial, as detailed in the 
extract below of the Art. 61.6 in the mentioned Regulation 536/2014:
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“Member States shall make the processes set out in paragraph 5 subject to appropriate 
and proportionate requirements to ensure subject safety and reliability and robustness of the 
data generated in the clinical trial. They shall subject the processes to regular inspections.”
3. Simplified labelling of diagnostic radiopharmaceuticals used as investigational 
medicinal products (IMPs) and auxiliary medicinal products (AMPs)
It should be noted that this exception for diagnostic radiopharmaceutical is only 
in the context of a clinical trial where the number of patients and the length of study 
is limited. Moreover, art 61.6 of Regulation 536/2014 leaves open the possibility for 
each Member State of having regular inspections with their specific requirements.
This situation shall be seen as totally different from the small-scale radiophar-
maceutical preparation on a routine basis, where bypassing the compliance with 
good manufacturing practices affecting the quality of the radiopharmaceuticals 
could have an impact on a much larger number of patients in the day-to-day usage.
8. Starting materials for the PET radiopharmaceuticals preparations
The definition of a starting material is depicted in part II of Good Manicuring 
Practices (GMPs) [28] as shown in the extract below:
“An Active Substance Starting Material is a raw material, intermediate, or an active 
substance that is used in the production of an active substance and that is incorporated 
as a significant structural fragment into the structure of the active substance. An Active 
Substance Starting Material can be an article of commerce, a material purchased from one 
or more suppliers under contract or commercial agreement or produced in-house. Active 
Substance Starting Materials normally have defined chemical properties and structure”.
In case of the PET Radiopharmaceutical preparations, the main starting material 
is the chemical precursor whose definition is stated in the European Pharmacopoeia 
monograph 2902 named Chemical Precursors for Radiopharmaceuticals 
Preparations [29] as follows:
“Chemical precursors are non-radioactive substances obtained by chemical synthesis 
for combination with a radionuclide”.
In this monograph a risk assessment is requested whenever the radiopharma-
ceutical preparation is required for special needs of individual patients, provided 
that non individual monograph for the precursor is available. Likewise, differences 
between diagnostic use versus therapeutic use as well as the frequency of use shall 
be taken into account for the risk assessment. These indications are fully described 
in the paragraph below extracted from monograph 2902:
“Where a chemical precursor not described in an individual monograph of the 
European Pharmacopoeia is used in a radiopharmaceutical preparation prepared for the 
special needs of individual patients, the need for compliance with this general mono-
graph is decided in the light of a risk assessment.
This risk assessment takes account of:
• the quality of the chemical precursor and the information available for quality 
evaluation.
• any further processing after radiolabelling (which may or may not include 
purification before administration to the patient).
• the amount used to prepare a patient dose (e.g., diagnostic use versus thera-
peutic use) and the frequency of administration to the patient.”
Radiopharmaceuticals
14
The quality of the chemical precursors is critical to ensure the final quality 
of the radiopharmaceutical product. These precursors are used in radiolabel-
ling reactions for the preparation of the radioactive pharmaceutical ingredients 
(APIs) that are not isolated and/or fully analysed before incorporation in the final 
radiopharmaceutical preparation. For this reason, according to the Guideline 
on Radiopharmaceuticals [16] they should satisfy the Note for Guidance on 
Summary of Requirements for Active Substances in Part II of the Dossier [30].
It is relevant to remark that during the radiopharmaceutical quality dossier 
preparation to be submitted to the relevant authorities, the information on chemi-
cal precursors including those for synthesis of PET radiopharmaceuticals may be 
presented in a separate Section 3.2.S following the requirements of the Common 
Technical Document (CTD). This is stated in the European Commission Document 
Volume 2B Notice to Applicants Medicinal products for human use [15]. This 
approach must be followed for both marketing authorisation (MAA) and clinical 
trial authorization (CTA) applications.
In particular, the module 3 of the CTD covers chemical and pharmaceutical 
data including data for biological/ biotechnological products. This module has two 
parts: drug substance and drug product part. In the case of the chemical precursor 
of the radiopharmaceutical preparation, it should comply with the drug substance 
requirements section.
The Guideline on Radiopharmaceuticals [16] describes the specific additional 
information that needs to be submitted in relation to radiopharmaceuticals, when 
preparing the radiopharmaceutical quality dossier. The following sections included 
in Table 3 should be completed:
The information depicted in Table 3 can be submitted by the applicant to the 
regulatory authorities following two different procedures:
1. Firstly, according to the current EU Guideline on the ASMF procedure (Ac-
tive Substance Master File Guideline [31]. The main objective of it, is to allow 
valuable confidential intellectual property or ‘know-how’ of the manufacturer 
of the active substance (ASM) to be protected, while at the same time allowing 
the Applicant or Marketing Authorisation (MA) holder to take full respon-
sibility for the medicinal product and the quality and quality control of the 
active substance. In the case of radiopharmaceuticals preparation would be the 
chemical precursor manufacturer the ASMF holder.
2. Secondly, the applicant could submit the information included in Table 3, 
through the CEP procedure (certificate of suitability of the monograph of the 
European Pharmacopoeia) that is granted by the European Directorate for 
the Quality of Medicines (EDQM). It is stated in the Directive 2001/83/EC [6] 
amended by 2003/63/EC [32] as it is shown in the extract below:
“Where the active substance and/or a raw and starting material or excipient(s) are 
the subject of a monograph of the European Pharmacopoeia, the applicant can apply 
for a certificate of suitability that, where granted by the European Directorate for the 
Quality of Medicines, shall be presented in the relevant section of this Module. Those 
certificates of suitability of the monograph of the European Pharmacopoeia are deemed 
to replace the relevant data of the corresponding sections described in this Module. The 
manufacturer shall give the assurance in writing to the applicant that the manufacturing 
process has not been modified since the granting of the certificate of suitability by the 
European Directorate for the Quality of Medicines.”
On the contrary, if the applicant did not want to use either of the two previous 
procedures, all sections could be submitted directly to the regulatory authorities.
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These requirements are mandatory for both clinical trial and marketing authorisa-
tion applications, however they should also be compulsory for radiopharmaceuticals 
prepared outside the marketing authorisation track, regardless of the category to which 
they belong (magistral formula, special product, etc...). A clear example where this 
information is required is Spain. Hence, to prepare PET radiopharmaceutical outside 
the marketing authorisation track under the regulatory framework of article 47.1c in 
RD 1345/2007 [23], it is always necessary to submit the previously mentioned module 
3 of CTD to the regulatory authority (AEMPS). In this way, the quality of the prepara-
tion in both chemical precursor and final radiopharmaceutical would be ensured.
It is noteworthy that, as a general rule, the information provided by the chemical 
precursor manufacturers is very limited. It is usually only submitted the chemi-
cal precursor structure, the specification, and some batch results. Obviously, this 
information should not be considered as sufficient to guaranty the quality of the 
final product.
Regarding the stability studies, stress testing of the chemical precursor must 




• 3.2.S.1.3 General Properties
3.2.S.2 Manufacture
• 3.2.S.2.1 Manufacturer(s)
• 3.2.S.2.2 Description of Manufacturing Process and Process Controls
3.2.S.2.3 Control of Materials
3.2.S.2.4 Controls of Critical Steps and Intermediates
3.2.S.2.5 Process Validation and/or Evaluation
3.2.S.2.6 Manufacturing Process Development
3.2.S.3 Characterisation
• 3.2.S.3.1 Elucidation of Structure and other Characteristics
• 3.2.S.3.2 Impurities
3.2.S.4 Control of Drug Substance
• 3.2.S.4.1 Specification
• 3.2.S.4.2 Analytical Procedures
• 3.2.S.4.3 Validation of Analytical Procedures
• 3.2.S.4.4 Batch Analyses
• 3.2.S.4.5 Justification of Specification
3.2.S.5 Reference Standards or Materials
3.2.S.6 Container Closure System
3.2.S.7 Stability
• 3.2.S.7.1 Stability Summary and Conclusions
• 3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment
• 3.2.S.7.3 Stability Data
Table 3. 
Module 3 of common technical document (CTD) drug substance part.
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stability studies to cover storage, shipment, and subsequent use, according to ICH 
Q 1 A (R2) Stability Testing of new Drug Substances and Products [33]. However, 
the chemical precursor manufacturer is not obliged to stablish a retest period, but in 
case no retest period is defined, a statement should be included that the precursor 
is tested immediately before the drug product manufacture. In case retest period 
had not been proposed, the radiopharmacy unit would test the chemical precursor 
before its use. The details on the retest period information should be considered by 
the drug product manufacturer, in the case under analyse, the radiopharmacy unit.
A relevant problem is that, in most cases, radiopharmacy units are not aware of 
this fact and even when they knew it, they would not be equipped for performing 
such tests.
Regarding compliance of GMPs, according to Good Manufacturing Practices 
Part II: Basic Requirements for Active Substances used as Starting Material [28] the 
following requirements should be complied:
• The identity of the chemical precursor should be verified at least of each batch.
• Full analyses on at least three batches should be conducted before reducing 
in-house testing.
• As a minimum, a full analysis should be performed at appropriate intervals 
and compared with the Certificates of Analysis.
• Reliability of Certificates of Analysis should be checked at regular intervals.
Considering that radiopharmacy units are not usually equipped to fulfil these 
requirements, the requested tests could be outsourced following the requirements 
of GMP Chapter 7 Outsourced Activities [34].
Hence, there should be written procedures describing the receipt, identification, 
quarantine, storage, handling, sampling, testing, and approval or rejection of mate-
rials. Additionally, for all starting materials and critical components, only qualified 
vendors should be used. Vendor qualification can be established by an audit, by 
responses to a Quality Assurance questionnaire, or simply based on experience with 
this supplier (e.g., the hospital pharmacy). In any case, vendor qualification should 
always be documented.
As we can see, special attention should be devoted to the purity and control 
methods for all starting materials, reactants, chemicals, reagents, and solvents used 
in synthesis and purification regardless they are licensed or unlicensed radiophar-
maceuticals. Furthermore, it should be stressed that radiopharmaceuticals contain-
ing radionuclides of short physical half-life (e.g., PET radiopharmaceuticals), can 
be released before all results on finished product testing are available, therefore the 
consistency of all the steps in the production process has a crucial importance.
9. Conclusion
This text aimed to provide an overview on the radiopharmaceutical preparations 
in the European Union, focusing on the main differences between national laws 
regarding the non-licensed small-scale preparations, while analysing whether the 
quality expectations on them are really achieved or not. It went through a recap 
of the alternative methods to control sterility in radiopharmaceuticals, types of 
radiopharmaceutical marketing authorisations, differences between preparation 
and manufacturing of radiopharmaceuticals, available guidelines related to the 
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quality in radiopharmaceuticals field, radiopharmaceuticals preparation outside the 
marketing track in the European Union and starting materials quality requirements 
for PET Radiopharmaceuticals preparations.
The intention was to raise some of the hot topics in the scientific community 
around the radiopharmaceutical compounds, considered a special group of medi-
cines, that can be prepared outside the marketing authorisation track. In particular, 
small-scale preparations at non-commercial sites which represent an important seg-
ment, despite a lack of harmonisation in the regulation leads to extreme differences 
in the application and availability of radiopharmaceuticals across Europe.
It is noteworthy, that most radiopharmaceutical preparations are sterile 
injectable products. As developed along the text, the existing regulation on the 
manufacture of sterile medicines, shall imply the need of a harmonisation in the 
European Union regarding the requirements applicable in the small-scale prepara-
tion of radiopharmaceuticals, which are currently considered not clear enough. A 
possible way forward might be the compliance with Good Manufacturing Practices 
(GMPs) properly adapted to the special nature of small-scale preparation of 
radiopharmaceuticals.
Moreover, special attention should be put on the quality assurance process for 
non-licensed starting materials, given that the final radiopharmaceuticals quality 
chiefly depends on it.
To sum up, the radiopharmacists community should try to achieve a proven 
quality, efficacy, and safety for our radiopharmaceuticals, regardless if they are 
licensed or unlicensed products, both in large or small-scale preparations.
Abbreviation list
AIDS Acquired Immune Deficiency Syndrome
AEMPS Agencia Española del Medicamento y Productos Sanitarios
AMPs Auxiliary Medicinal Products
ALARA As Low As Reasonably Achievable
API Active Pharmaceutical Ingredient
ASMF Active Substance Master File Guideline
CEP Certificate of suitability of the monograph of the European 
Pharmacopoeia
CHMP Committee for Medicinal Products for Human Use
CTA Clinical Trial Authorization
CTD Common Technical Document
DEFT Direct Epifluorescent Filter Technique
EANM European Association of Nuclear Medicine
EDQM European Directorate for the Quality of Medicines & HealthCare
EFPIA European Federation of Pharmaceutical Industries Associations
EMA European Medicines Agency
EU European Union
FDA Food and Drug Administration
GMPs Good Manufacturing Practices
HIV Human Immunodeficiency Virus
ICH International Council for Harmonisation
IMPs Investigational Medicinal Products
JPMA Japan Pharmaceutical Manufacturers Association
MAA Marketing Authorisation Application
MAH Marketing Authorisation Holder
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MHRA The Medicines and Healthcare Products Regulatory Agency (UK)
NAT Nucleic Acid Amplification Techniques
PET Positron emission tomography
PhRMA Pharmaceutical Research and Manufacturers of America
PICs Pharmaceutical inspection convention, pharmaceutical inspection 
co-operation scheme
SPC Summary of Product Characteristics
SPECT Single Photon Emission Computed Tomography
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